scholarly journals Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever

2016 ◽  
pp. bcr2016216941 ◽  
Author(s):  
Nikolaos K Gatselis ◽  
Panagiotis Skendros ◽  
Konstantinos Ritis ◽  
George N Dalekos
2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 1222.2-1222
Author(s):  
A. Polat ◽  
C. Saglam ◽  
Y.G. Kurt ◽  
G. Basbozkurt ◽  
B. Sozeri ◽  
...  

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_5) ◽  
Author(s):  
W Messadi ◽  
A Salmi ◽  
N Cherif

Abstract Background Biotherapy result of spectacular advances in genetics and research in molecular and cellular biology, has considerably improved the management of rheumatic and autoinflammatory diseases in children. The Objective is to assess the efficacy and tolerance of biotherapy in pediatrics Methods A retro-prospective study was carried out in the Pediatric Department B at the pediatric rheumatology consultation, university hospital center. An operating sheet was drawn up including epidemiological, clinical, paraclinical and therapeutic data of the cases diagnosed as well as their evolution on biotherapy. Results 26 children received treatment with biotherapy. 73% presented with JIA (54% systemic, 19% polyarticular with positive RF, 19% severe uveitis, and 4% familial Mediterranean fever. 4% behçet disease The mean time to start biotherapy was 12 months [2–48]. There is a clear clinical and biological improvement for 93% of patients. Etanercept was effective in polyarticular-progressive JIA, Adalimumab in oligoarthritis with severe uveitis, Tocilizumab in systemic forms of JIA and Anakinra in familial Mediterranean fever resistant to colchicine and systemic arthritis. The adverse reactions noted were: one case of tuberculosis, hepatic cytolysis in 4 cases, and one case of psoriasis. Conclusion The introduction of biotherapy in pediatric has considerably improved the management of inflammatory rheumatic diseases and transformed the prognosis of these chronic diseases. The maintenance of the good response to treatment and the good tolerance of biotherapy must be evaluated prospectively over the long term.


BMJ ◽  
1977 ◽  
Vol 2 (6090) ◽  
pp. 808-808 ◽  
Author(s):  
M Levy ◽  
M Eliakim

2012 ◽  
Vol 31 (8) ◽  
pp. 1267-1271 ◽  
Author(s):  
Z. Birsin Özçakar ◽  
Selçuk Yüksel ◽  
Mesiha Ekim ◽  
Fatoş Yalçınkaya

1978 ◽  
Vol 93 (5) ◽  
pp. 876-878 ◽  
Author(s):  
Thomas J.A. Lehman ◽  
Robert S. Peters ◽  
Virgil Hanson ◽  
Arthur D. Schwabe

2019 ◽  
Vol 51 (7) ◽  
pp. 2289-2291
Author(s):  
Hazen Sarıtaş ◽  
Damla Ors Sendogan ◽  
Gizem Kumru ◽  
Rezzan Eren Sadioglu ◽  
Neval Duman ◽  
...  

2008 ◽  
Vol 53 (4) ◽  
pp. 1-3
Author(s):  
E Sengul ◽  
K Yildiz ◽  
Y Topcu ◽  
A Yilmaz

Malignant mesothelioma is a rare tumor. The most common localization of mesothelioma is pleura. It rarely arises from the peritoneum. It has been suggested that familial Mediterranean fever (FMF) may cause the development of peritoneal mesothelioma. We describe a case of malignant peritoneal mesothelioma in a hemodialysis patient with FMF. The patient was a 56 year old female. A history of FMF was present since her childhood. She did not use colchicine and suffered from recurrent ascites. To the best of our knowledge, this is the seventh case of FMF diagnosed as having malignant peritoneal mesothelioma in the medical literature.


2009 ◽  
Vol 37 (2) ◽  
pp. 422-425 ◽  
Author(s):  
MERAV LIDAR ◽  
RON KEDEM ◽  
YAACOV BERKUN ◽  
PNINA LANGEVITZ ◽  
AVI LIVNEH

Objective. To characterize familial Mediterranean fever (FMF) in Ashkenazi patients, a Jewish subgroup in which FMF has rarely been described before.Methods. A retrospective analysis, comparing demographic, clinical, and genetic measures of the cohort of Ashkenazi Jewish patients with FMF (n = 57), followed at the National Center for FMF in Israel, to age and sex matched patients of Iraqi Jewish (n = 62) and North African Jewish (NAJ; n = 61) origin.Results. Age at disease onset and diagnosis was earlier in NAJ than among Ashkenazi and Iraqi patients. Family history of FMF was described by only 30% of Ashkenazi patients as opposed to the majority of Iraqi and NAJ patients (p = 0.001). The frequency of abdominal and febrile attacks was similar among the 3 groups, while chest and joint attacks were far less common in Ashkenazi and Iraqi compared to NAJ patients. A good response to colchicine was noted in a similar proportion of Ashkenazi and Iraqi patients (82–84%) as opposed to only 56% of NAJ patients (p = 0.0001). Proteinuria, renal failure, and amyloidosis were most frequent among the NAJ patients (18, 6.6, and 9.8% compared to 5.3, 0, and 3.5% and 1.6, 0, and 0% in Ashkenazi and Iraqi patients, respectively).Conclusion. Ashkenazi patients with FMF stand at the mildest end of the clinical spectrum of FMF. This is notwithstanding the tendency for amyloidosis, the frequency of which is not trivial and which deserves particular awareness.


Sign in / Sign up

Export Citation Format

Share Document